- Home
- VRNA vs KYMR Comparison
VRNA vs KYMR Comparison
Compare VRNA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- KYMR
- Stock Information
- Founded
- VRNA 2005
- KYMR 2015
- Country
- VRNA United Kingdom
- KYMR United States
- Employees
- VRNA N/A
- KYMR N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- VRNA Health Care
- KYMR Health Care
- Exchange
- VRNA Nasdaq
- KYMR Nasdaq
- Market Cap
- VRNA 3.2B
- KYMR 3.0B
- IPO Year
- VRNA 2017
- KYMR 2020
- Fundamental
- Price
- VRNA $42.26
- KYMR $41.95
- Analyst Decision
- VRNA Strong Buy
- KYMR Buy
- Analyst Count
- VRNA 6
- KYMR 16
- Target Price
- VRNA $43.83
- KYMR $54.00
- AVG Volume (30 Days)
- VRNA 1.0M
- KYMR 456.9K
- Earning Date
- VRNA 11-04-2024
- KYMR 10-31-2024
- Dividend Yield
- VRNA N/A
- KYMR N/A
- EPS Growth
- VRNA N/A
- KYMR N/A
- EPS
- VRNA N/A
- KYMR N/A
- Revenue
- VRNA $5,624,000.00
- KYMR $87,563,000.00
- Revenue This Year
- VRNA N/A
- KYMR N/A
- Revenue Next Year
- VRNA $644.06
- KYMR $33.16
- P/E Ratio
- VRNA N/A
- KYMR N/A
- Revenue Growth
- VRNA 1127.95
- KYMR 86.92
- 52 Week Low
- VRNA $11.39
- KYMR $22.35
- 52 Week High
- VRNA $43.73
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- VRNA 63.97
- KYMR 40.45
- Support Level
- VRNA $41.24
- KYMR $41.66
- Resistance Level
- VRNA $43.73
- KYMR $44.17
- Average True Range (ATR)
- VRNA 1.45
- KYMR 2.28
- MACD
- VRNA 0.09
- KYMR -0.34
- Stochastic Oscillator
- VRNA 72.16
- KYMR 11.84
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.